´ëÇѺñ¸¸ÇÐȸ (¿Â¶óÀÎ&¿ÀÇÁ¶óÀÎ º´Çà) Á¦43ȸ Ãá°è¿¬¼ö°Á : 2022-02-27±³À°ÀÏÀÚ : 2022-02-27
±³À°Àå¼Ò : ¿Â¶óÀÎ&¿ÀÇÁ¶óÀÎ µ¿½Ã °³ÃÖ (*¿ÀÇÁ¶óÀÎ: ¼¼Á¾´ëÇб³ ±¤°³Åä°ü)
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ&¿ÀÇÁ¶óÀÎ º´Çà) Á¦43ȸ Ãá°è¿¬¼ö°ÁÂÁÖÃÖ±â°ü : ´ëÇѺñ¸¸ÇÐȸ
´ã´çÀÚ : °¶ó¿µ
¿¬¶ôó : 02-6941-0888
À̸ÞÀÏ :
obesity@kosso.or.kr ±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¼Ò¾Æû¼Ò³â°ú, °¡Á¤ÀÇÇаú
Âü¼®¿¹»óÀοø : 500¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 13 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 70,000¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 02-27 Convention C 09:00~09:30 Digital therapeutics, ºñ¸¸Áø·áÀÇ À̳뺣ÀÌ¼Ç ±èÁÖ¿µ(ºÐ´ç¼¿ï´ëº´¿ø °¡Á¤ÀÇÇаú)
±³À°½Ã°£ 02-27 Convention C 09:30~10:00 ºñ¸¸Áø·áÀÇ »õ·Î¿î ½Ãµµ, microbiomeÀÇ ¼¼°è ¹ÚÁøÈ£(¼¿ï´ëº´¿ø °¡Á¤ÀÇÇаú)
±³À°½Ã°£ 02-27 Convention C 10:00~10:30 ºñ¸¸ÀÇ À¯ÀüÇÐ, ¾îµð±îÁö ¿ÍÀÖ³ª È«°æ¿ø(Å׶óÁ¨ ÀÌÅؽº)
±³À°½Ã°£ 02-27 Convention A 09:00~09:30 ÀçÈ°Ä¡·á ÁßÀÌÁö¸¸ ¿îµ¿ÇÒ ¼ö ÀÖ¾î¿ä - ÀçÈ°Ä¡·á ÁßÀÎ ºñ¸¸ ȯÀÚ¿¡¼ÀÇ ¿îµ¿Ä¡·á ÃÖ¹®¿µ(¼¿ï¹éº´¿ø ½ºÆ÷Ã÷ÀÇÇнÇ)
±³À°½Ã°£ 02-27 Convention A 09:30~10:00 ¾ÏÀ» °Þ¾úÁö¸¸ ºñ¸¸ °ü¸®ÇØ¾ß ÇÕ´Ï´Ù - ¾Ï°æÇèÀÚÀÇ ºñ¸¸°ü¸® ½ÅÁø¿µ(°Ç±¹´ëº´¿ø °¡Á¤ÀÇÇаú)
±³À°½Ã°£ 02-27 Convention A 10:00~10:30 Á¤½Å°ú ¾àÀ» º¹¿ë ÁßÀÌÁö¸¸ ºñ¸¸ Ä¡·á °¡´ÉÇÕ´Ï´Ù - Á¤½ÅÁúȯÀÌ Àִ ȯÀÚ¿¡¼ÀÇ ºñ¸¸ Ä¡·á °ÁöÇö(°Ç¾ç´ëº´¿ø °¡Á¤ÀÇÇаú)
ÈÞ½Ä 02-27 10:30~10:45 ÈÞ½Ä ()
±³À°½Ã°£ 02-27 Convention C 10:45~11:15 ¸¶¾à·ù ½Ä¿å¾ïÁ¦Á¦ ´Ü±â »ç¿ëÀÇ ÀÇÀÇ ±èº¸¿¬(ºÎõ¼øõÇ⺴¿ø ³»ºÐºñ³»°ú)
±³À°½Ã°£ 02-27 Convention C 11:15~11:45 ¸¶¾à·ù ½Ä¿å¾ïÁ¦Á¦ »çÀü¾Ë¸®¹Ì ¹× ¾ÈÀü»ç¿ë ±âÁØÀÇ ÀÇÀÇ ±èÁ¤È¯(ÀÇÁ¤ºÎÀ»Áö´ëº´¿ø °¡Á¤ÀÇÇаú)
Åä·Ð 02-27 Convention C 11:45~12:15 ÆгÎÅäÀÇ ±è¼º¼ö, ¹Ú¹Î¼ö, ±èÁ¤È¯(Ãæ³²´ëº´¿ø, ¼¿ïNDº´¿ø, ÀÇÁ¤ºÎÀ»Áö´ëº´¿ø)
±³À°½Ã°£ 02-27 Convention A 10:45~11:15 LDL-C : The lower is the better ÀÌ»ó¿(°æÈñÀÇ´ë °æÈñ´ëº´¿ø ³»ºÐºñ´ë»ç³»°ú)
±³À°½Ã°£ 02-27 Convention A 11:15~11:45 LDL-C : The ealier is the better ÇѺ´´ö(°í·ÁÀÇ´ë ¾È¾Ïº´¿ø °¡Á¤ÀÇÇаú)
±³À°½Ã°£ 02-27 Convention A 11:45~12:15 Early combination treatment in T2DM È«ÁØÈ(À»ÁöÀÇ´ë ´ëÀüÀ»Áö´ëº´¿ø ³»ºÐºñ³»°ú)
±³À°½Ã°£ 02-27 Convention C 12:15~12:45 Phentermine + Topiramate ER : Uses, Efficacy & Adverse event, and More ±è¹Ì°æ(°¡Å縯´ëÇб³ ¿©Àǵµ¼º¸ðº´¿ø ³»ºÐºñ³»°ú)
±³À°½Ã°£ 02-27 Convention C 12:45~13:15 Exploring the extended benefits of Ipragliflozin focusing on NAFLD ¹ÚÁ¤È¯(ÇѾç´ëº´¿ø ³»ºÐºñ´ë»ç³»°ú)
ÈÞ½Ä 02-27 13:15~13:30 ÈÞ½Ä ()
±³À°½Ã°£ 02-27 Convention C 13:30~14:00 ¼Ò¾Æû¼Ò³âºñ¸¸°ú ÀÌ»óÁöÁúÇ÷Áõ °¼®Áø(°è¸íÀÇ´ë µ¿»êº´¿ø ¼Ò¾Æû¼Ò³â°ú)
±³À°½Ã°£ 02-27 Convention C 14:00~14:30 ¼Ò¾Æû¼Ò³âºñ¸¸°ú ºñ¾ËÄڿüºÁö¹æ°£Áúȯ ±è¹ÌÁø(¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø ¼Ò¾Æû¼Ò³â°ú)
±³À°½Ã°£ 02-27 Convention C 14:30~15:00 ¼Ò¾Æû¼Ò³âºñ¸¸°ú °íÇ÷¾Ð ±è¼ºÇý(Â÷ÀÇ´ë ºÐ´çÂ÷º´¿ø ¼Ò¾Æû¼Ò³â°ú)
±³À°½Ã°£ 02-27 Convention A 13:30~14:00 ½ÄÈÄ°íÇ÷´ç°ú ¿îµ¿¿ä¹ý ¹Ú¼¼Àº(°ºÏ»ï¼ºº´¿ø)
±³À°½Ã°£ 02-27 Convention A 14:00~14:30 ´ç´¢º´Ä¡·áÀÇ ³·Àº¼øÀÀµµ ±Øº¹Çϱâ ÃÖÁ¾ÇÑ(°Ç±¹´ëÇб³º´¿ø)
±³À°½Ã°£ 02-27 Convention A 14:30~15:00 Controlling dyslipidemia and CV risk with Atorvastatin and Ezetimibe ¹ÚÇü±Ô(¼øõÇ⼿ﺴ¿ø)
ÈÞ½Ä 02-27 15:00~15:15 ÈÞ½Ä ()
±³À°½Ã°£ 02-27 Convention C 15:15~15:45 °íÇ÷¾Ð Áø·áÁöħ °ü·Ã issue ½ÅÁøÈ£(ÇѾç´ëº´¿ø ½ÉÀå³»°ú)
±³À°½Ã°£ 02-27 Convention C 15:45~16:15 ÀÌ»óÁöÁúÇ÷Áõ Áø·áÁöħ °ü·Ã issue ±è»óÇö(¼¿ï´ëº´¿ø ¼øȯ±â³»°ú)
±³À°½Ã°£ 02-27 Convention C 16:15~16:45 ´ç´¢º´ Áø·áÁöħ °ü·Ã issue ¹®¹Î°æ(¼¿ï´ë º¸¶ó¸Åº´¿ø ³»ºÐºñ³»°ú)
±³À°½Ã°£ 02-27 Convention A 15:15~15:45 ´Ü¼øÈ÷ ³ªÀÕ»ì? ³ëÀκñ¸¸ÀÇ Á߿伺°ú Ư¼ö¼º ±è¾çÇö(°í·Á´ëº´¿ø °¡Á¤ÀÇÇаú)
±³À°½Ã°£ 02-27 Convention A 15:45~16:15 ³ëÀÎ ´ÙÀ̾îÆ®, ¿µ¾ç Ä¡·á ³ëÇÏ¿ì ÀÓÈñ¼÷(°æÈñ´ëÀÓ»ó¿µ¾ç´ëÇпø)
±³À°½Ã°£ 02-27 Convention A 16:15~16:45 ¾Ë¾ÆµÎ¸é ÁÁÀº ³ëÀκñ¸¸ ¿îµ¿Ã³¹æ ¼¹ÎÁ¤(¼¿ï½Ã¸³¼ö¶ô¾ç·Î¿ø)